Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PGE1 program in erectile dysfunction: etiopathogenic and pharmacologic aspects]

J L Ruiz Rubio1, I Fernández González, J C Ruiz Rojas

  • 1Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid.

Actas Urologicas Espanolas
|July 1, 1996
PubMed
Summary

Prostaglandin E1 (PGE1) self-injection therapy is effective for erectile dysfunction. Patient compliance is linked to disease severity, with minimal complications observed in this study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usefulness and acceptance of telephone monitoring by a virtual assistant for patients with COVID-19 following discharge.

Revista clinica espanola·2021
Same author

[Usefulness and acceptance of telephone monitoring by a virtual assistant for patients with COVID-19 following discharge].

Revista clinica espanola·2021
Same author

Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.

Actas urologicas espanolas·2020
Same author

PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.

European journal of cancer (Oxford, England : 1990)·2010
Same author

Quantitative (1) H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings.

Magnetic resonance in medicine·2010
Same author

[TVT and TOT for surgical correction of female stress urinary incontinence. Comparison between techniques].

Archivos espanoles de urologia·2008

Area of Science:

  • Urology
  • Andrology
  • Pharmacology

Background:

  • Prostaglandin E1 (PGE1) has been utilized for erectile dysfunction (ED) since 1986.
  • Self-injection therapy with PGE1, without co-administered drugs, is increasingly favored for ED due to its ease of use and low complication rates.

Purpose of the Study:

  • To analyze the outcomes of a self-injection program using PGE1 monotherapy in 66 patients with erectile dysfunction.
  • To evaluate patient compliance and complication rates associated with PGE1 self-injection therapy.

Main Methods:

  • Retrospective analysis of 66 patients undergoing PGE1 self-injection monotherapy for ED.
  • Follow-up duration averaged 9.8 months (range 1-39 months).
  • Patient demographics and etiological factors (vascular, diabetic, psychological) were recorded.

Related Experiment Videos

Main Results:

  • The mean patient age was 55 years.
  • Vascular (42%), diabetic (19%), and psychological (21%) were the primary etiological groups.
  • Significant dose increases over time were noted in vascular and diabetic patients.
  • Program compliance correlated with the severity of the underlying disease, particularly in vascular and diabetic patients.
  • Reported local complications included pain (19.6%), prolonged erection (3%), and priapism (1.5%).

Conclusions:

  • PGE1 self-injection monotherapy is a viable treatment option for erectile dysfunction.
  • Disease severity significantly impacts patient compliance in PGE1 self-injection programs.
  • While generally safe, potential local complications require monitoring.